Our data demonstrated that the combined Lp-PLA2 and YKL-40 RNAi group exhibited enhanced amelioration of plaque inflammation compared to single Lp-PLA2 or YKL-40 RNAi, thus providing a potential therapeutic approach for the treatment of atherosclerosis. This evidence concerns the gene CHI3L1 and atherosclerosis.